section name header

Pronunciation

al-BEN-da-zole

Classifications

Therapeutic Classification: anthelmintics

Indications

REMS


Action

  • Inhibits tubulin polymerization, resulting in the loss of cytoplasmic microtubules.
Therapeutic effects:
  • Death of affected larval form of susceptible parasites.

Spectrum:

Pharmacokinetics

Absorption: Poorly absorbed following oral administration because of extensive first-pass hepatic metabolism, resulting in rapid conversion to albendazole sulfoxide, the active metabolite.

Distribution: Widely distributed.

Protein Binding: 70% bound to plasma proteins.

Metabolism/Excretion: After conversion to the sulfoxide metabolite, further hepatic metabolism to inactive compounds occurs. <1% excreted in urine; excretion is primarily via bile.

Half-Life: Albendazole sulfoxide: 8–12 hr.

Time/Action Profile

(blood levels of albendazole sulfoxide)

ROUTEONSETPEAKDURATION
POunknown2–5 hrunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: reversible alopecia

GI: liver enzymes ( in hydatid disease), abdominal pain (hydatid disease only), nausea/vomiting ( in neurocysticercosis)

Hemat: AGRANULOCYTOSIS, GRANULOCYTOPENIA, PANCYTOPENIA

Neuro: headache ( in neurocysticercosis), intracranial pressure ( in neurocysticercosis), dizziness/vertigo, meningeal signs (in neurocysticercosis only)

Misc: fever (hydatid disease only)

Interactions

Drug-drug:

Route/Dosage

Hydatid Disease

Neurocysticercosis

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Albenza